Roche Acquires PathAI for $750 Million to Advance AI-Powered Pathology
- Roche, a Swiss pharmaceutical company, has signed an agreement to acquire PathAI, a company based in Boston.
- Under the terms of the agreement, Roche will pay $750 million upfront for the acquisition of the company.
- The deal includes performance-based incentives that could result in an additional $300 million for PathAI if the company achieves certain milestones.
The input is an RSS fragment and aggregator snippet from STAT.
Roche, a Swiss pharmaceutical company, has signed an agreement to acquire PathAI, a company based in Boston. The acquisition is intended to accelerate the application of artificial intelligence to assist pathologists in the diagnosis of disease.
Under the terms of the agreement, Roche will pay $750 million upfront for the acquisition of the company.
The deal includes performance-based incentives that could result in an additional $300 million for PathAI if the company achieves certain milestones.
The transaction is expected to close in the second half of 2026.
Andy Beck, the cofounder and chief executive of PathAI, stated that the partnership marks a new era for PathAI
and will help the company pursue its goal of improving patient outcomes through the use of AI-powered pathology at a greater speed and scale.
Roche’s global infrastructure and expertise will bring our digital diagnostics technology to patients worldwide.
Andy Beck, chief executive and cofounder of PathAI